H
31.87
-0.16 (-0.50%)
| Previous Close | 32.03 |
| Open | 32.03 |
| Volume | 140,156 |
| Avg. Volume (3M) | 708,416 |
| Market Cap | 1,830,106,624 |
| Price / Earnings (TTM) | 12.16 |
| Price / Earnings (Forward) | 8.65 |
| Price / Sales | 2.50 |
| Price / Book | 2.56 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2025 - 8 Aug 2025 |
| Profit Margin | 20.50% |
| Operating Margin (TTM) | 30.45% |
| Diluted EPS (TTM) | 2.62 |
| Quarterly Revenue Growth (YOY) | 19.50% |
| Quarterly Earnings Growth (YOY) | 18.90% |
| Total Debt/Equity (MRQ) | 24.63% |
| Current Ratio (MRQ) | 3.67 |
| Operating Cash Flow (TTM) | 222.67 M |
| Levered Free Cash Flow (TTM) | 143.41 M |
| Return on Assets (TTM) | 12.81% |
| Return on Equity (TTM) | 24.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Harmony Biosciences Holdings, I | Bearish | Mixed |
AIStockmoo Score
0.8
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.75 |
|
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 11.64% |
| % Held by Institutions | 92.91% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 70.00 (HC Wainwright & Co., 119.64%) | Buy |
| Median | 49.00 (53.75%) | |
| Low | 48.00 (Mizuho, 50.61%) | Buy |
| 48.00 (UBS, 50.61%) | Buy | |
| Average | 55.20 (73.20%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 32.14 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Oppenheimer | 02 Jun 2025 | 61.00 (91.40%) | Buy | 35.56 |
| Mizuho | 15 May 2025 | 48.00 (50.61%) | Buy | 34.23 |
| Needham | 07 May 2025 | 49.00 (53.75%) | Buy | 33.44 |
| 06 May 2025 | 49.00 (53.75%) | Buy | 32.05 | |
| UBS | 28 Apr 2025 | 48.00 (50.61%) | Buy | 29.36 |
| HC Wainwright & Co. | 08 Apr 2025 | 70.00 (119.64%) | Buy | 28.13 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 11 Jun 2025 | Announcement | Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025 |
| 05 Jun 2025 | Announcement | Harmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA Litigation |
| 04 Jun 2025 | Announcement | Harmony Biosciences to Participate in Goldman Sachs 46th Annual Global Healthcare Conference |
| 06 May 2025 | Announcement | Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance |
| 29 Apr 2025 | Announcement | Harmony Biosciences to Report First Quarter 2025 Financial Results on May 6, 2025 |
| 08 Apr 2025 | Announcement | Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |